Earthquake in pharma sector! Real time hall of 8 legendary stocks from Sun Pharma to Cipla | Pharma Stocks News Sun Pharma Biocon Aurobindo Dr Reddy Lupin Cipla Trump Tariff

Veteran company Sun Pharma suffered the biggest setback. The company’s stock fell 5% to ₹ 1,547, which is its 52-Veik low level. However, it later showed recovery and by 10:15 am, the stock broke 2.14% trading at Rs 1,592.50.

After Sun Pharma, Trump’s decision was the biggest impact on Biocon. The company’s shares fell 3.3% trading at Rs 344. By 10 am, the stock slipped 2.91% and trading at Rs 345.60.

Jides could not escape from Trump’s tariff. Its shares fell by 2.8% and came to Rs 990. By 10 pm in the morning, the stock was seen doing business at this level.

Aurobindo Pharma shares fell 2.4% to close at 1,070 on Thursday. On Friday morning, it is trading at Rs 1,090.60 by 0.58% by 10 pm on Friday morning. The company has a major focus on the US market and may increase the pressure on the earnings from branded drugs. However, it can get partial relief due to its generic portfolio.

Dr. Reddy’s stock recorded a decline of 0.52% by 10 pm and was trading at Rs 1,268.60. The company is one of the top suppliers in the American generic market. So at the moment, tariff relaxation can benefit it, but will remain a challenge for the part of branded products.

Lupine shares were traded at Rs 1,945.90 by 0.90% till 10 am, which closed at Rs 1,923.30 on Thursday. The company has a strong generic business in the US, but after the Trump’s policy, investors are currently alert. In the coming time, if the tariff also increases on the generic, its effect may be deeper.

Cipla’s stock also fell 2% to close at Rs 1,480 on Thursday. Trading at Rs 1,498.50 by 0.74% declined by 10 pm on Friday morning. The company’s hold in the US market is strong, but due to dependence on branded and specialty drugs, it created pressure. However, generic exports can balance it some.